Highlights Pharma Mar, S.A.

Stocks

PHM

ES0169501022

Pharmaceuticals

Market Closed - BME Other stock markets 19:35:02 11/06/2026 +04			After hours 20:08:23
86.05 ^EUR	+3.24%		86.20	+0.17%

06-01	PharmaMar Announces European Commission Approves Zepzelca With Atezolizumab For Extended-Stage Small Cell Lung Cancer	CI
06-01	Pharma Mar says EC approves Zepzelca with atezolizumab for first-line maintenance in SCLC	RE

Highlights

06-01	PharmaMar Announces European Commission Approves Zepzelca With Atezolizumab For Extended-Stage Small Cell Lung Cancer	CI
06-01	Pharma Mar says EC approves Zepzelca with atezolizumab for first-line maintenance in SCLC	RE
05-21	Pharma Mar to propose dividend of 1.00 euro/shr	RE
04-30	Pharma Mar Q1 EBITDA 2.7 mln euros	RE
04-29	Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-20	Specialised Therapeutics Announces Approval of Zepzelca in Combination with Atezolizumab as First-Line Maintenance Treatment for Extensive-Stage Small Cell Lung Cancer in Australia and Singapore	CI
04-20	PharmaMar Says Small-Cell Lung Cancer Therapy Combo Secures Approval in Australia, Singapore	MT
04-20	Pharma Mar's Zepzelca and Tecentriq combination gets approval in Australia and Singapore	RE
03-27	EU Medicines Agency Backs Approval for Pharma Mar's Maintenance Drug for Extensive-stage Small Cell Lung Cancer	MT
03-27	Pharma Mar receives positive opinion from EMA recommending approval of Zepzelca with atezolizumab	RE
03-27	Pharma Mar completes acquisition of treasury shares for 7.0 mln euros	RE
03-23	Pharma Mar gets Taiwan approval for its lung cancer treatment as first-line maintenance therapy	RE
03-19	Globant And PharmaMar Form Strategic Alliance To Accelerate Oncology Research With AI	CI
03-13	Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-27	Pharma Mar FY net profit 75.0 mln euros	RE
11-28	UAE Regulator OKs Pharma Mar, Immedica's Combo Therapy for Small Cell Lung Cancer	MT
11-24	Pharma Mar's Zepzelca Combo Wins Swiss Approval for Small Cell Lung Cancer	MT
11-24	Pharma Mar says Swiss Medical Authority approves Zepzelca and Atezolizumab combination for lung cancer	RE
30/10/25	Pharma Mar 9-month net profit 15.3 million euros	RE
15/10/25	Pharma Mar Gets $50 Million Milestone Payment After Securing US Nod for Small Cell Lung Cancer Drug	MT
15/10/25	Pharma Mar receives $50 mln from Jazz Pharmaceuticals for FDA approval of Zepzelca in combination with Atezolizumab	RE
03/10/25	Pharma Mar says FDA approves Zepzelca and Atezolizumab for advanced lung cancer	RE
31/07/25	Pharma Mar H1 net profit 19.4 mln euros, to carry out capital reduction	RE
30/07/25	Pharma Mar, S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25/06/25	For Distribution from share premium account	FA